The global scleroderma diagnostics and therapeutics market was valued at US$ 2.2 Bn in 2022 and is expected to grow at a CAGR of 8.7% from 2023 to 2031, reaching US$ 4.6 Bn by the end of 2031. The market is witnessing significant growth as healthcare providers, pharmaceutical companies, and research institutions intensify efforts to improve the diagnosis and treatment of this rare autoimmune...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek